BioCardia, Inc. 8-K

What Happened
BioCardia, Inc. (BCDA) announced on February 3, 2026 (Form 8‑K) that echocardiography data from its CardiAMP cell therapy program for the treatment of heart failure has been accepted for a Late‑Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, taking place March 2–4, 2026 in Boston, Massachusetts. A company press release about the acceptance is attached to the 8‑K as Exhibit 99.1.

Key Details

• Form 8‑K filed: February 3, 2026.
• Presentation: Late‑Breaking Clinical Trial Oral Presentation at THT (Technology and Heart Failure Therapeutics).
• Data type: Echocardiography data from the CardiAMP cell therapy program targeting heart failure.
• Conference: March 2–4, 2026, Boston, MA; press release attached as Exhibit 99.1 to the 8‑K.

Why It Matters
The acceptance ensures BioCardia will publicly present clinical echocardiography results from its CardiAMP program at a major heart‑failure meeting, creating a near‑term event (March 2–4, 2026) where clinicians, researchers and investors can review the data. Investors can monitor the THT presentation and the company’s press materials for details on the data and any implications for CardiAMP’s clinical progress.